News Releases
by Year
2020
Dec. 28, 2020 (PDF/113KB) Licensing
Consolidated Subsidiary Myovant and Pfizer Enter Into Collaboration to Develop and Commercialize Relugolix
Dec. 28, 2020 (PDF/188KB) Finances
Sumitomo Dainippon Pharma Concludes Positive Impact Finance Agreement with Sumitomo Mitsui Trust Bank
Dec. 25, 2020 Sustainability
Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
Dec. 24, 2020 (PDF/93KB) Products
Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
Dec. 21, 2020 (PDF/102KB) Products
Myovant Sciences Announces FDA Approval of ORGOVYX (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Dec. 18, 2020 (PDF/2,408KB) Sustainability
ESG Meeting (Discussion with Investors)
Nov. 25, 2020 (PDF/30KB) R&D
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
Nov. 13, 2020 (PDF/82KB) Corporate
Sumitovant Enters into an Agreement for "Going Private" Transaction with its U.S. Subsidiary Urovant
Nov. 04, 2020 Finances
Posted Video of Investors Meeting Presentation for Q2 FY2020 [Webcast]
Oct. 28, 2020 (PDF/1,170KB) Finances
Investors Meeting Presentation for Q2 FY2020 (April 1 to September 30, 2020）
Oct. 28, 2020 (PDF/436KB) Finances
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2021
Oct. 28, 2020 (PDF/268KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2021 [IFRS]
Oct. 28, 2020 (PDF/129KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Oct. 27, 2020 (PDF/223KB) R&D
Joint Research and Development Agreement with Drawbridge Health, Inc. on Innovative Blood Sampling Solution for Lifestyle Diseases
Oct. 08, 2020 (PDF/169KB) Corporate
Sumitomo Chemical and Sumitomo Dainippon Pharma Announce Establishment and Inception of Operations of a Joint Venture Company for CDMO Business in the field of Regenerative Medicine and Cell Therapy
Oct. 08, 2020 (PDF/29KB) Corporate
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Oct. 06, 2020 (PDF/275KB) Products
Sunovion Announces the Commercial Launch of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
Sep. 30, 2020 (PDF/98KB) R&D
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep. 23, 2020 (PDF/98KB) Corporate
Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan
Sep. 18, 2020 (PDF/542KB) Others
Sumitomo Dainippon Pharma and KDDI Announce Start of Initiatives to Create New Platform for Communication between MRs and HealthCare Professionals Using XR
Sep. 17, 2020 (PDF/80KB) Corporate
Sumitomo Dainippon Pharma Announces Change in Executive Officer
Sep. 04, 2020 (PDF/104KB) Finances
Sumitomo Dainippon Pharma Determines Issuance Conditions for Publicly Offered Hybrid Bonds (Subordinated Bonds)
Sep. 01, 2020 (PDF/123KB) Corporate
Sumitomo Dainippon Pharma Announces Organizational Realignment and Change in Executive Officer
Aug. 18, 2020 (PDF/46KB) R&D
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Aug. 06, 2020 (PDF/52KB) Corporate
Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Aug. 05, 2020 (PDF/355KB) R&D
Sumitomo Dainippon Pharma, Sompo Japan, and Aikomi Announce Collaboration on R&D and Commercialization of Digital Devices for Dementia and Nursing Care
Aug. 03, 2020 Finances
Posted Conference Call for Q1 FY2020 [Webcast]
Aug. 03, 2020 (PDF/120KB) R&D
Save Medical and Sumitomo Dainippon Pharma Announce Signing of Joint Development Agreement for Mobile App for Management of Type 2 Diabetes and Commencement of Clinical Study
Jul. 30, 2020 (PDF/101KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Imeglimin Hydrochloride for the Treatment of Type 2 Diabetes in Japan
Jul. 30, 2020 (PDF/1,044KB) Finances
Presentation Material（First Quarter Financial Results for FY2020）
Jul. 30, 2020 (PDF/267KB) Finances
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2021
Jul. 30, 2020 (PDF/265KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2021[IFRS]
Jul. 30, 2020 (PDF/110KB) Finances
Sumitomo Dainippon Pharma Announces Issuance of Publicly Offered Hybrid Bonds (Subordinated Bonds)
Jul. 20, 2020 (PDF/139KB) Sustainability
Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment
Jul. 16, 2020 (PDF/83KB) Sustainability
Sumitomo Dainippon Pharma Contributes to the Relief Efforts for the Heavy Rain Event of July 2020 in Japan
Jul. 07, 2020 (PDF/224KB) R&D
Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
Jun. 26, 2020 (PDF/81KB) Corporate
Sumitomo Dainippon Pharma Announces Transfer of a Fixed Asset
Jun. 24, 2020 (PDF/50KB) R&D
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jun. 23, 2020 (PDF/50KB) R&D
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Jun. 22, 2020 (PDF/157KB) Corporate
Notice of the Filing of a Petition for Inter Partes Review (IPR) to USPTO for Method of Use Patent of LATUDA
Jun. 19, 2020 (PDF/27KB) Corporate
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
Jun. 16, 2020 (PDF/516KB) Products
Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson's Disease OFF Episodes
Jun. 04, 2020 (PDF/161KB) Products
Sumitomo Dainippon Pharma Announces Launch of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
Jun. 02, 2020 (PDF/47KB) R&D
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Jun. 01, 2020 (PDF/104KB) R&D
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
May 29, 2020 (PDF/109KB) Corporate
Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
May 22, 2020 (PDF/895KB) Products
Sunovion Announces U.S. FDA Approval of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
May 19, 2020 Finances
Posted Video of Investors Meeting Presentation for FY2019 (Year ended March 31, 2020) [Webcast]
May 13, 2020 (PDF/1,658KB) Finances
Investors Meeting Presentation for FY2019 (Year ended March 31, 2020)
May 13, 2020 (PDF/531KB) Finances
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2020
May 13, 2020 (PDF/593KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2020 [IFRS]
May 13, 2020 (PDF/80KB) Corporate
Sumitomo Dainippon Pharma Announces Change in Board of Directors
Apr. 28, 2020 (PDF/108KB) Finances
Sumitomo Dainippon Pharma Revises Financial Forecasts
Apr. 28, 2020 (PDF/253KB) Sustainability
Donation of Medical Protective Equipment (Face Shields, Masks and Gowns) to Support Measures against Coronavirus Disease 2019 (COVID-19)
Apr. 24, 2020 (PDF/1,143KB) R&D
Supplementary Material (Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine)
Apr. 24, 2020 (PDF/301KB) R&D
Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine
Apr. 23, 2020 (PDF/50KB) R&D
Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
Apr. 22, 2020 (PDF/50KB) R&D
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
Apr. 16, 2020 (PDF/287KB) R&D
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion's SEP-363856 for the Treatment of Schizophrenia
Apr. 03, 2020 (PDF/262KB) R&D
The GHIT Fund Awards Grant for the Development of a New Malaria Transmission-Blocking Vaccine by Ehime University and Sumitomo Dainippon Pharma
Mar. 31, 2020 (PDF/51KB) Licensing
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
Mar. 31, 2020 (PDF/85KB) Sustainability
Donations to the Kitasato Institute's Project for COVID-19 for Early Identification of Therapeutic Medicine for its Treatment
Mar. 25, 2020 (PDF/164KB) Products
Sumitomo Dainippon Pharma Announces the Approval of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Mar. 25, 2020 (PDF/107KB) Products
Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
Mar. 18, 2020 (PDF/83KB) Corporate
Sumitomo Dainippon Pharma Announces Change in Executive Officer and Other Key Position
Mar. 10, 2020 (PDF/47KB) R&D
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar. 09, 2020 R&D
Posted Video of R&D Meeting [Webcast]
Mar. 06, 2020 (PDF/187KB) R&D
Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Mar. 03, 2020 (PDF/10,286KB) R&D
Posted Presentation Material (R&D Meeting)
Mar. 03, 2020 (PDF/122KB) Corporate
Sumitomo Dainippon Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Mar. 02, 2020 (PDF/139KB) Corporate
Sumitomo Dainippon Pharma Announces Investment in MPM Oncology Innovations Fund
Feb. 04, 2020 Finances
Posted Conference Call for Q3 FY2019 [Webcast]
Jan. 31, 2020 (PDF/96KB) Finances
Announcement of Borrowing Funds
Jan. 30, 2020 (PDF/1,387KB) Finances
Presentation Material (Third Quarter Financial Results for FY2019)
Jan. 30, 2020 (PDF/435KB) Finances
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2020
Jan. 30, 2020 (PDF/381KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2020 [IFRS]
Jan. 30, 2020 (PDF/253KB) R&D
Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study
Jan. 29, 2020 (PDF/102KB) Sustainability
Donations for the Prevention of Pneumonia Caused by the New Coronavirus in China
Jan. 17, 2020 (PDF/97KB) Corporate
Sumitomo Dainippon Pharma announces Personnel Change
Jan. 09, 2020 (PDF/228KB) Corporate
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life‐Saving Treatment for Post‐Lung Transplant Patients to the Altavant Pipeline
Jan. 06, 2020 (PDF/20KB) R&D
Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder